Colorectal cancer and RASSF family-A special emphasis on RASSF1A

International Journal of Cancer

Volumn 132, Issue 2, 2013, Pages 251-258

  Fernandes, Maria Sofia ^a   Carneiro, Fátima ^a,b   Oliveira, Carla ^a,b   Seruca, Raquel ^a,b  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

Author keywords

colorectal cancer; methylation; RAS signaling; RASSF RASSF1A; tumor suppressor

Indexed keywords

BIOLOGICAL MARKER; RAS ASSOCIATION DOMAIN FAMILY PROTEIN; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; RAS ASSOCIATION DOMAIN FAMILY PROTEIN F2; RAS ASSOCIATION DOMAIN FAMILY PROTEIN F5; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; COLORECTAL CANCER; DNA METHYLATION; DRUG TARGETING; GENE ACTIVATION; GENE INACTIVATION; GENE MUTATION; GENE SILENCING; HUMAN; MICROTUBULE; ONCOGENE K RAS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN FAMILY; PROTEIN METHYLATION; REVIEW;

ANIMALS; APOPTOSIS; CELL CYCLE CHECKPOINTS; COLORECTAL NEOPLASMS; DNA METHYLATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEINS;

EID: 84869503619     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.27696     Document Type: Review

References (95)

1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Markowitz SD, Bertagnolli MM,. Molecular origins of cancer: molecular basis of colorectal cancer. N Engl J Med 2009; 361: 2449-60.
3. De Roock W, De Vriendt V, Normanno N, et al. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011; 12: 594-603.
4. Oliveira C, Velho S, Moutinho C, et al. KRAS and BRAF oncogenic mutations in MSS colorectal carcinoma progression. Oncogene 2007; 26: 158-63.
5. Velho S, Moutinho C, Cirnes L, et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis? BMC Cancer 2008; 8: 255.
6. Velho S, Oliveira C, Ferreira A, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer 2005; 41: 1649-54.
7. Oliveira C, Westra JL, Arango D, et al. Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status. Hum Mol Genet 2004; 13: 2303-11.
8. Cox AD, Der CJ,. The dark side of Ras: regulation of apoptosis. Oncogene 2003; 22: 8999-9006.
9. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D,. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer 2011; 11: 761-74.
10. Overmeyer JH, Maltese WA,. Death pathways triggered by activated Ras in cancer cells. Front Biosci 2011; 16: 1693-713.
11. Richter AM, Pfeifer GP, Dammann RH,. The RASSF proteins in cancer: from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796: 114-28.
12. Oliveira C, Velho S, Domingo E, et al. Concomitant RASSF1A hypermethylation and KRAS/BRAF mutations occur preferentially in MSI sporadic colorectal cancer. Oncogene 2005; 24: 7630-4.
13. Cunningham D, Atkin W, Lenz HJ, et al. Colorectal cancer. Lancet 2010; 375: 1030-47.
14. Tops CM, Wijnen JT, Hes FJ,. Introduction to molecular and clinical genetics of colorectal cancer syndromes. Best Pract Res Clin Gastroenterol 2009; 23: 127-46.
15. Velho S, Corso G, Oliveira C, et al. KRAS signaling pathway alterations in microsatellite unstable gastrointestinal cancers. Adv Cancer Res 2010; 109: 123-43.
16. Domingo E, Espin E, Armengol M, et al. Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation. Genes Chromosomes Cancer 2004; 39: 138-42.
17. Lubomierski N, Plotz G, Wormek M, et al. BRAF mutations in colorectal carcinoma suggest two entities of microsatellite-unstable tumors. Cancer 2005; 104: 952-61.
18. Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature 2002; 418: 934.
19. Ekstrand AI, Jonsson M, Lindblom A, et al. Frequent alterations of the PI3K/AKT/mTOR pathways in hereditary nonpolyposis colorectal cancer. Fam Cancer 2010; 9: 125-9.
20. Bos JL, Rehmann H, Wittinghofer A,. GEFs and GAPs: critical elements in the control of small G proteins. Cell 2007; 129: 865-77.
21. Sebolt-Leopold JS, Herrera R,. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004; 4: 937-47.
22. Liu P, Cheng H, Roberts TM, et al. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 2009; 8: 627-44.
23. Vavvas D, Li X, Avruch J, et al. Identification of Nore1 as a potential Ras effector. J Biol Chem 1998; 273: 5439-42.
24. Dammann R, Li C, Yoon JH, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumor suppressor locus 3p21.3. Nat Genet 2000; 25: 315-9.
25. Lerman MI, Minna JD,. The 630-kb lung cancer homozygous deletion region on human chromosome 3p21.3: identification and evaluation of the resident candidate tumor suppressor genes. The international lung cancer chromosome 3p21.3 tumor suppressor gene consortium. Cancer Res 2000; 60: 6116-33.
26. van der Weyden L, Adams DJ,. The Ras-association domain family (RASSF) members and their role in human tumorigenesis. Biochim Biophys Acta 2007; 1776: 58-85.
27. Gordon M, Baksh S,. RASSF1A: not a prototypical Ras effector. Small Gtpases 2011; 2: 148-57.
28. Donninger H, Vos MD, Clark GJ,. The RASSF1A tumor suppressor. J Cell Sci 2007; 120: 3163-72.
29. Agathanggelou A, Cooper WN, Latif F,. Role of the Ras-association domain family 1 tumor suppressor gene in human cancers. Cancer Res 2005; 65: 3497-508.
30. Dammann R, Schagdarsurengin U, Strunnikova M, et al. Epigenetic inactivation of the Ras-association domain family 1 (RASSF1A) gene and its function in human carcinogenesis. Histol Histopathol 2003; 18: 665-77.
31. Agathanggelou A, Honorio S, Macartney DP, et al. Methylation associated inactivation of RASSF1A from region 3p21.3 in lung, breast and ovarian tumors. Oncogene 2001; 20: 1509-18.
32. Burbee DG, Forgacs E, Zochbauer-Muller S, et al. Epigenetic inactivation of RASSF1A in lung and breast cancers and malignant phenotype suppression. J Natl Cancer Inst 2001; 93: 691-9.
33. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci USA 2001; 98: 7504-9.
34. Lo KW, Kwong J, Hui AB, et al. High frequency of promoter hypermethylation of RASSF1A in nasopharyngeal carcinoma. Cancer Res 2001; 61: 3877-81.
35. Yoon JH, Dammann R, Pfeifer GP,. Hypermethylation of the CpG island of the RASSF1A gene in ovarian and renal cell carcinomas. Int J Cancer 2001; 94: 212-7.
36. Sakamoto N, Terai T, Ajioka Y, et al. Frequent hypermethylation of RASSF1A in early flat-type colorectal tumors. Oncogene 2004; 23: 8900-7.
37. Wagner KJ, Cooper WN, Grundy RG, et al. Frequent RASSF1A tumor suppressor gene promoter methylation in Wilms' tumor and colorectal cancer. Oncogene 2002; 21: 7277-82.
38. van Engeland M, Roemen GM, Brink M, et al. K-ras mutations and RASSF1A promoter methylation in colorectal cancer. Oncogene 2002; 21: 3792-5.
39. Miranda E, Destro A, Malesci A, et al. Genetic and epigenetic changes in primary metastatic and nonmetastatic colorectal cancer. Br J Cancer 2006; 95: 1101-7.
40. Gonzalo V, Lozano JJ, Munoz J, et al. Aberrant gene promoter methylation associated with sporadic multiple colorectal cancer. PLoS One 2010; 5: e8777.
41. Miladi-Abdennadher I, Abdelmaksoud-Damak R, Ayadi L, et al. Hypermethylation of RARbeta2 correlates with high COX-2 expression and poor prognosis in patients with colorectal carcinoma. Tumor Biol 2010; 31: 503-11.
42. Abouzeid HE, Kassem AM, Abdel Wahab AH, et al. Promoter hypermethylation of RASSF1A, MGMT, and HIC-1 genes in benign and malignant colorectal tumors. Tumor Biol 2011; 32: 845-52.
43. Noda H, Kato Y, Yoshikawa H, et al. Frequent involvement of ras-signaling pathways in both polypoid-type and flat-type early-stage colorectal cancers. J Exp Clin Cancer Res 2006; 25: 235-42.
44. Greenspan EJ, Jablonski MA, Rajan TV, et al. Epigenetic alterations in RASSF1A in human aberrant crypt foci. Carcinogenesis 2006; 27: 1316-22.
45. Tommasi S, Pinto R, Petriella D, et al. Oncosuppressor methylation: a possible key role in colon metastatic progression. J Cell Physiol 2011; 226: 1934-9.
46. Ahlquist T, Bottillo I, Danielsen SA, et al. RAS signaling in colorectal carcinomas through alteration of RAS, RAF, NF1, and/or RASSF1A. Neoplasia 2008; 10: 680-6.
47. Derks S, Postma C, Carvalho B, et al. Integrated analysis of chromosomal, microsatellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumor suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis 2008; 29: 434-9.
48. Dong SM, Lee EJ, Jeon ES, et al. Progressive methylation during the serrated neoplasia pathway of the colorectum. Mod Pathol 2005; 18: 170-8.
49. Harada K, Hiraoka S, Kato J, et al. Genetic and epigenetic alterations of Ras signalling pathway in colorectal neoplasia: analysis based on tumor clinicopathological features. Br J Cancer 2007; 97: 1425-31.
50. Van der Auwera I, Bovie C, Svensson C, et al. Quantitative methylation profiling in tumor and matched morphologically normal tissues from breast cancer patients. BMC Cancer 2010; 10: 97.
51. Dammann R, Yang G, Pfeifer GP,. Hypermethylation of the cpG island of Ras association domain family 1A (RASSF1A), a putative tumor suppressor gene from the 3p21.3 locus, occurs in a large percentage of human breast cancers. Cancer Res 2001; 61: 3105-9.
52. An B, Kondo Y, Okamoto Y, et al. Characteristic methylation profile in CpG island methylator phenotype-negative distal colorectal cancers. Int J Cancer 2010; 127: 2095-105.
53. Tommasi S, Dammann R, Jin SG, et al. RASSF3 and NORE1: identification and cloning of two human homologues of the putative tumor suppressor gene RASSF1. Oncogene 2002; 21: 2713-20.
54. Lee CK, Lee JH, Lee MG, et al. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 2010; 10: 577.
55. Hesson L, Dallol A, Minna JD, et al. NORE1A, a homologue of RASSF1A tumor suppressor gene is inactivated in human cancers. Oncogene 2003; 22: 947-54.
56. Akino K, Toyota M, Suzuki H, et al. The Ras effector RASSF2 is a novel tumor-suppressor gene in human colorectal cancer. Gastroenterology 2005; 129: 156-69.
57. Hesson LB, Wilson R, Morton D, et al. CpG island promoter hypermethylation of a novel Ras-effector gene RASSF2A is an early event in colon carcinogenesis and correlates inversely with K-ras mutations. Oncogene 2005; 24: 3987-94.
58. Park HW, Kang HC, Kim IJ, et al. Correlation between hypermethylation of the RASSF2A promoter and K-ras/BRAF mutations in microsatellite-stable colorectal cancers. Int J Cancer 2007; 120: 7-12.
59. Nosho K, Yamamoto H, Takahashi T, et al. Genetic and epigenetic profiling in early colorectal tumors and prediction of invasive potential in pT1 (early invasive) colorectal cancers. Carcinogenesis 2007; 28: 1364-70.
60. Lee BB, Lee EJ, Jung EH, et al. Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clin Cancer Res 2009; 15: 6185-91.
61. Eckfeld K, Hesson L, Vos MD, et al. RASSF4/AD037 is a potential ras effector/tumor suppressor of the RASSF family. Cancer Res 2004; 64: 8688-93.
62. Rodriguez-Viciana P, Sabatier C, McCormick F,. Signaling specificity by Ras family GTPases is determined by the full spectrum of effectors they regulate. Mol Cell Biol 2004; 24: 4943-54.
63. Vos MD, Ellis CA, Bell A, et al. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J Biol Chem 2000; 275: 35669-72.
64. Vos MD, Ellis CA, Elam C, et al. RASSF2 is a novel K-Ras-specific effector and potential tumor suppressor. J Biol Chem 2003; 278: 28045-51.
65. Ortiz-Vega S, Khokhlatchev A, Nedwidek M, et al. The putative tumor suppressor RASSF1A homodimerizes and heterodimerizes with the Ras-GTP binding protein Nore1. Oncogene 2002; 21: 1381-90.
66. Kuzmin I, Gillespie JW, Protopopov A, et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res 2002; 62: 3498-502.
67. Tommasi S, Dammann R, Zhang Z, et al. Tumor susceptibility of Rassf1a knockout mice. Cancer Res 2005; 65: 92-8.
68. van der Weyden L, Tachibana KK, Gonzalez MA, et al. The RASSF1A isoform of RASSF1 promotes microtubule stability and suppresses tumorigenesis. Mol Cell Biol 2005; 25: 8356-67.
69. Avruch J, Praskova M, Ortiz-Vega S, et al. Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases. Methods Enzymol 2006; 407: 290-310.
70. Khokhlatchev A, Rabizadeh S, Xavier R, et al. Identification of a novel Ras-regulated proapoptotic pathway. Curr Biol 2002; 12: 253-65.
71. Praskova M, Khoklatchev A, Ortiz-Vega S, et al. Regulation of the MST1 kinase by autophosphorylation, by the growth inhibitory proteins, RASSF1 and NORE1, and by Ras. Biochem J 2004; 381: 453-62.
72. Oh HJ, Lee KK, Song SJ, et al. Role of the tumor suppressor RASSF1A in Mst1-mediated apoptosis. Cancer Res 2006; 66: 2562-9.
73. Cooper WN, Hesson LB, Matallanas D, et al. RASSF2 associates with and stabilizes the proapoptotic kinase MST2. Oncogene 2009; 28: 2988-98.
74. Rabizadeh S, Xavier RJ, Ishiguro K, et al. The scaffold protein CNK1 interacts with the tumor suppressor RASSF1A and augments RASSF1A-induced cell death. J Biol Chem 2004; 279: 29247-54.
75. Baksh S, Tommasi S, Fenton S, et al. The tumor suppressor RASSF1A and MAP-1 link death receptor signaling to Bax conformational change and cell death. Mol Cell 2005; 18: 637-50.
76. Vos MD, Dallol A, Eckfeld K, et al. The RASSF1A tumor suppressor activates Bax via MOAP-1. J Biol Chem 2006; 281: 4557-63.
77. Foley CJ, Freedman H, Choo SL, et al. Dynamics of RASSF1A/MOAP-1 association with death receptors. Mol Cell Biol 2008; 28: 4520-35.
78. Shivakumar L, Minna J, Sakamaki T, et al. The RASSF1A tumor suppressor blocks cell cycle progression and inhibits cyclin D1 accumulation. Mol Cell Biol 2002; 22: 4309-18.
79. Whang YM, Kim YH, Kim JS, et al. RASSF1A suppresses the c-Jun-NH2-kinase pathway and inhibits cell cycle progression. Cancer Res 2005; 65: 3682-90.
80. Fenton SL, Dallol A, Agathanggelou A, et al. Identification of the E1A-regulated transcription factor p120 E4F as an interacting partner of the RASSF1A candidate tumor suppressor gene. Cancer Res 2004; 64: 102-7.
81. Rong R, Jin W, Zhang J, et al. Tumor suppressor RASSF1A is a microtubule-binding protein that stabilizes microtubules and induces G2/M arrest. Oncogene 2004; 23: 8216-30.
82. Song MS, Song SJ, Ayad NG, et al. The tumor suppressor RASSF1A regulates mitosis by inhibiting the APC-Cdc20 complex. Nat Cell Biol 2004; 6: 129-37.
83. Liu L, Baier K, Dammann R, et al. The tumor suppressor RASSF1A does not interact with Cdc20, an activator of the anaphase-promoting complex. Cell Cycle 2007; 6: 1663-5.
84. Donninger H, Hesson L, Vos M, et al. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 2010; 30: 2608-20.
85. Vos MD, Martinez A, Ellis CA, et al. The pro-apoptotic Ras effector Nore1 may serve as a Ras-regulated tumor suppressor in the lung. J Biol Chem 2003; 278: 21938-43.
86. Calvisi DF, Donninger H, Vos MD, et al. NORE1A tumor suppressor candidate modulates p21CIP1 via p53. Cancer Res 2009; 69: 4629-37.
87. Moshnikova A, Frye J, Shay JW, et al. The growth and tumor suppressor NORE1A is a cytoskeletal protein that suppresses growth by inhibition of the ERK pathway. J Biol Chem 2006; 281: 8143-52.
88. Ikeda M, Hirabayashi S, Fujiwara N, et al. Ras-association domain family protein 6 induces apoptosis via both caspase-dependent and caspase-independent pathways. Exp Cell Res 2007; 313: 1484-95.
89. Allen NP, Donninger H, Vos MD, et al. RASSF6 is a novel member of the RASSF family of tumor suppressors. Oncogene 2007; 26: 6203-11.
90. Falvella FS, Manenti G, Spinola M, et al. Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 2006; 25: 3934-8.
91. Liu L, Tommasi S, Lee DH, et al. Control of microtubule stability by the RASSF1A tumor suppressor. Oncogene 2003; 22: 8125-36.
92. Dallol A, Agathanggelou A, Fenton SL, et al. RASSF1A interacts with microtubule-associated proteins and modulates microtubule dynamics. Cancer Res 2004; 64: 4112-6.
93. Song MS, Chang JS, Song SJ, et al. The centrosomal protein RAS association domain family protein 1A (RASSF1A)-binding protein 1 regulates mitotic progression by recruiting RASSF1A to spindle poles. J Biol Chem 2005; 280: 3920-7.
94. Vos MD, Martinez A, Elam C, et al. A role for the RASSF1A tumor suppressor in the regulation of tubulin polymerization and genomic stability. Cancer Res 2004; 64: 4244-50.
95. Dallol A, Agathanggelou A, Tommasi S, et al. Involvement of the RASSF1A tumor suppressor gene in controlling cell migration. Cancer Res 2005; 65: 7653-9.